CSIMarket
 
Vir Biotechnology Inc   (NASDAQ: VIR)
Other Ticker:  
 
 
Price: $5.4500 $0.04 0.739%
Day's High: $5.59 Week Perf: -3.54 %
Day's Low: $ 5.40 30 Day Perf: 4.41 %
Volume (M): 882 52 Wk High: $ 14.45
Volume (M$): $ 4,805 52 Wk Avg: $7.53
Open: $5.43 52 Wk Low: $4.32



 Market Capitalization (Millions $) 749
 Shares Outstanding (Millions) 137
 Employees 201
 Revenues (TTM) (Millions $) 21
 Net Income (TTM) (Millions $) -578
 Cash Flow (TTM) (Millions $) 188
 Capital Exp. (TTM) (Millions $) 7

Vir Biotechnology Inc
Vir Biotechnology Inc is a clinical-stage immunology company focused on developing therapies to treat infectious diseases.
The company was founded in 2016 by George Scangos, a former CEO of Biogen.
The company has its headquarters in San Francisco, California and operates in the United States and the United Kingdom.
Vir is focused on developing treatments for viral infections such as hepatitis B virus, respiratory syncytial virus (RSV), influenza, and novel coronaviruses like SARS-CoV-2.
The company is looking to leverage its expertise in immunology and virology to develop novel treatments that can improve patient outcomes and reduce the spread of infectious diseases.
Vir has a diverse pipeline of product candidates, including monoclonal antibodies, antivirals, and vaccines, that are being developed for a range of viral infections.
The company has several partnerships and collaborations with leading pharmaceutical companies, including GlaxoSmithKline, Biogen, and Alnylam.
Vir has a strong management team and scientific advisory board, comprising experts in virology, immunology, and drug development.
The company has raised over $2 billion in funding to support its research and development efforts.
Overall, Vir Biotechnology Inc is a promising biotech company with a focus on developing innovative treatments for infectious diseases.
With a strong pipeline of product candidates and partnerships with established pharmaceutical companies, the company is well-positioned to make a significant impact in the fight against viral infections.


   Company Address: 1800 Owens Street San Francisco 94158 CA
   Company Phone Number: 906-4324   Stock Exchange / Ticker: NASDAQ VIR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALEC     
AMGN        0.68% 
EXEL        0.68% 
GILD   -1.53%    
MRNA   -1.53%    
NVAX   -1.53%    
• View Complete Report
   



Business Update

A New Dawn in Chronic Hepatitis B Treatment Vir Biotechnologys Promising MARCH Study Results Illuminate the Path Ahead

Published Fri, May 9 2025 11:39 AM UTC

In the evolving landscape of hepatitis B treatment, the glimmer of hope shines brighter than ever, thanks to the recent findings from Vir Biotechnology, Inc.?s MARCH Phase 2 clinical study. Based in the vibrant city of San Francisco, this groundbreaking research sheds light on the efficacy of two innovative therapeutic agents, tobevibart and elebsiran, in tackling chronic he...

Business Update

Vir Biotechnology Inc. (NASDAQ VIR) has announced its participation in the upcoming 43rd Annual J.P. Morgan...

Published Wed, Dec 18 2024 3:03 PM UTC

Vir Biotechnology Showcases Promising Advances in Hepatitis Treatments at J.P. Morgan Healthcare Conference Vir Biotechnology Inc. (NASDAQ: VIR) has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference, set to take place on January 14, 2024, in San Francisco, California. Marianne De Backer, the company?s Chief Executive Officer, is slated...

Business Update

Vir Biotechnologys Bold Steps Navigating the Landscape of T-Cell Engagers and Chronic Hepatitis B Treatments,

Published Tue, Nov 26 2024 5:56 PM UTC

Vir Biotechnology s Bold Steps: Navigating the Landscape of T-Cell Engagers and Chronic Hepatitis B Treatments In the ever-evolving realm of biotechnology, Vir Biotechnology, Inc. is making waves with two significant developments in its therapeutic pipeline: the introduction of its innovative T-cell engager programs and promising results regarding hepatitis B treatments. Ann...

Business Update

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 R...

Published Tue, Nov 19 2024 5:10 AM UTC

Advancing the Frontier of Hepatitis Treatment: Vir Biotechnology s Breakthroughs in Clinical TrialsIn a groundbreaking development for the treatment of viral hepatitis, Vir Biotechnology, Inc. (NASDAQ: VIR) has reported significant advancements in its clinical trial programs targeting chronic hepatitis B (CHB) and chronic hepatitis delta (CHD). These strides include impress...

Business Update

Vir Biotechnologys Game-Changing Data A New Dawn for Chronic Hepatitis B Treatments,

Published Mon, Nov 18 2024 7:15 AM UTC

Tipping the Scale: Vir Biotechnology Advances Toward a Cure for Chronic Hepatitis BIn an era marked by remarkable advancements in biotechnology, Vir Biotechnology, Inc. (NASDAQ: VIR) has emerged as a beacon of hope for patients battling chronic hepatitis B. At the recent AASLD The Liver Meeting in San Francisco, the company unveiled promising end-of-treatment results from P...







Vir Biotechnology Inc's Segments
U S customers    40.83 % of total Revenue
Foreign customers GSK    -2.31 % of total Revenue
Foreign customers Other    61.48 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com